
Arcellx (ACLX) Stock Forecast & Price Target
Arcellx (ACLX) Analyst Ratings
Bulls say
Arcellx Inc. has demonstrated robust sales growth in its CAR T therapy, with Carvykti experiencing an average quarterly growth of 32% over the last 12 quarters and achieving a remarkable year-over-year revenue increase of 214%. The expanding adoption of CAR T therapy among community physicians, rising from 29% to 47%, indicates a growing acceptance and market penetration, further solidifying the company's position in the sector. Additionally, Arcellx's anito-cel product shows promise for capturing a significant share of the market, with projected sales of $4.7 billion by 2035, supported by its improved profile compared to existing options.
Bears say
The financial outlook for Arcellx, Inc. appears negative due to concerning clinical trial results, particularly the high rate of Grade 3-4 infections observed in its MajesTEC-1 study, which raises doubts about the safety and tolerability of its therapies. Additionally, the company's market share estimates for its anito-cel treatment align closely with consensus, yet its overall sales projections for the CAR T market in myeloma fall significantly below industry expectations, indicating potential revenue challenges. Furthermore, barriers to CAR T therapy adoption in community settings suggest that even with a promising portfolio, translating clinical success into widespread use and market penetration may remain problematic.
This aggregate rating is based on analysts' research of Arcellx and is not a guaranteed prediction by Public.com or investment advice.
Arcellx (ACLX) Analyst Forecast & Price Prediction
Start investing in Arcellx (ACLX)
Order type
Buy in
Order amount
Est. shares
0 shares